Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports...